RNAC
RNAC clinical trials: Cartesian Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Cartesian Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 12
- As lead sponsor
- 0
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
RNAC on the catalyst calendar · RNAC registry changes
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisCartesian Therapeutics · Myasthaenia GravisActive, not recruitingRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 2NCT07391605Descartes-08 in Autoantibody MyositisCartesian Therapeutics · Antisynthetase SyndromeRecruitingRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 5, 2026ActualPhase 2NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Cartesian Therapeutics · Myasthenia Gravis, GeneralizedActive, not recruitingRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics · Childhood-onset Systemic Lupus ErythematousRecruitingRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06038474Descartes-08 for Patients With Systemic Lupus ErythematosusCartesian Therapeutics · Systemic Lupus Erythematosus (SLE)Active, not recruitingRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2025ActualPhase 1NCT06304636Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaCartesian Therapeutics · Refractory Multiple MyelomaTerminatedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2021ActualPhase 1NCT03994705Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaCartesian Therapeutics · Multiple MyelomaTerminatedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2023ActualPhase 1NCT05113342Descartes-25 in Relapsed/Refractory Multiple MyelomaCartesian Therapeutics · Multiple MyelomaTerminatedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2022ActualPhase 2NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyCartesian Therapeutics · Multiple MyelomaCompletedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 9, 2022ActualPhase 1NCT04524962Study of Descartes-30 in Acute Respiratory Distress SyndromeCartesian Therapeutics · Acute Respiratory Distress SyndromeTerminatedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 4, 2022ActualPhase 2NCT04816526Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease...Cartesian Therapeutics · Myeloma MultipleTerminatedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2021ActualPhase 1NCT03448978Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaCartesian Therapeutics · Multiple MyelomaTerminatedRNACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner